1. 1,3,5-Triazine-azole Hybrids and their Anticancer Activity
   Hua Guo et al, 2020, Current Topics in Medicinal Chemistry CrossRef
2. Relevance of Translation Initiation in Diffuse Glioma Biology and its Therapeutic Potential
   Digregorio Marina et al, 2019, Cells CrossRef
3. Clinically Actionable Insights into Initial and Matched Recurrent Glioblastomas to Inform Novel Treatment Approaches
   H. P. Ellis et al, 2019, Journal of Oncology CrossRef
4. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
   Hua-fu Zhao et al, 2017, Molecular Cancer CrossRef
5. Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update
   Mayra Colardo et al, 2021, International Journal of Molecular Sciences CrossRef
6. Proteasome Inhibitors against Glioblastoma—Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine
   Agata Gozdz, 2023, Current Oncology CrossRef
7. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier
   Kaijun Di et al, 2016, Neuro-Oncology CrossRef
8. Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma
   Amir Barzegar Behrooz et al, 2022, International Journal of Molecular Sciences CrossRef
9. Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner
   Maria Beatrice Morelli et al, 2017, Oncotarget CrossRef
10. Oncogenic RAS-induced CK1α drives nuclear FOXO proteolysis
    F Zhang et al, 2018, Oncogene CrossRef
11. Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance
    Wenjun Yu et al, 2017, Leukemia & Lymphoma CrossRef
12. Targeting Cell Cycle Proteins in Brain Cancer
    Isabelle Ferry et al, 2018, Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy CrossRef
13. Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B‑cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3
    Ting Yuan et al, 2019, Oncology Letters CrossRef